UK's Labyrinthine Regulations Stalling Regenerative Medicine
By Nuala Moran
Wednesday, July 3, 2013
LONDON Problems with the regulatory framework and a lack of coordination is holding back development of regenerative therapies, delaying both health and economic benefits. Changes are needed to give investors confidence and clear the path to commercialization, according to a report on regenerative medicine in the UK, published last week. Private investors are reluctant to put money into regenerative medicine because of the high risk of failure to translate promising science into reimbursable treatments.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.